Zydus Lifesciences Ltd.
BSE: 532321 | NSE: ZYDUSLIFE
Mid Cap | Pharmaceuticals & Drugs
927.15
-19.95 (-2.11%) Zydus Lifesciences informs about press release
Date: 06-10-2022Zydus Lifesciences has informed that it enclosed a copy of press release dated October 6, 2022, titled ‘Zydus receives final approval from USFDA and 180 days shared exclusivity for Brivaracetam Tablets’.
The above information is a part of company’s filings submitted to BSE.